News

Tendyne Holdings Inc. has secured $25 million in an oversubscribed Series C financing led by Apple Tree Partners, along with Boulle Group members and other existing investors. 

Cytori Stem Cell Therapy Heart Failure Treatments PRECISE Trial

Cytori Therapeutics announced publication of safety and efficacy data from a 36 month European clinical trial of Cytori Cell Therapy in patients with chronic ischemic heart failure. 

April 18, 2014 — New research presented at the 34th annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) demonstrated the CorMatrix particulate extracellular...

April 18, 2014 — A University of California, San Diego scientist has developed a new biomaterial that could potentially treat heart attacks. Karen Christman, Ph.D., associate professor of...

Corevalve beats surgery, ACC 2014, TAVR vs surgery, Edwards lawsuit

The U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's CoreValve transcatheter aortic valve replacement (TAVR) system in the United...

 Mitralign Inc. has completed enrollment in a study in Europe investigating its lead device, the Mitralign System, in patients with functional mitral regurgitation (FMR).

April 10, 2014 — CardioKinetix Inc. announced results of a pooled analysis study of the catheter-based Parachute ventricular partitioning device. Twelve-month clinical results from 111...

April 7, 2014 — A first-ever randomized head-to-head comparison of two devices commonly used to treat aortic stenosis finds balloon-expandable transcatheter valves (such as the Edwards Sapien)...

Corevalve beats surgery, ACC 2014, TAVR vs surgery

The key trial presented at the 2014 American College of Cardiology (ACC) that will likely be the one attendees will remember “they were there for” in the years to come was data showing...

April 1, 2014 — Medtronic Inc. announced the one-year results of the Melody transcatheter pulmonary valve (TPV) U.S. post-approval study, which found that real-world use of the Melody TPV was...

atrial fibrillation, LARIAT

Doctors at the Stony Brook Heart Institute Electrophysiology Lab are using a new nonsurgical technique called the Lariat Suture Delivery Device to treat patients with atrial fibrillation who...

Surgeons in France have successfully replaced the aortic valve in two patients without opening the chest during surgery....

Cardiac Stem Cells Regeneration Therapy

Generating new cardiac muscle from human embryonic stem cells (hESCs) and/or induced pluripotent stem cells (...

Privately held On-X Life Technologies Inc. (On-X LTI) launched its European marketing campaign for the On-X Plus 1.5 Aortic Heart Valve in concert with its Great Britain distributor Vascutek Corp...

Cardiac stem cells regeneration therapy clinical trial study

Marty Greenfield lives with crushing pain every day due to angina. He has suffered a heart attack, and a coronary bypass procedure and angioplasty have provided little relief. His doctor referred...

Stem Cell Therapy Gene Cardiac Regeneration

After a heart attack, there is often permanent damage to a portion of the heart. This happens, in part, because cardiac muscle cells are terminally differentiated and cannot proliferate after...

Edwards Lifesciences Fortis Mitral Transcatheter Valve System Heart Valve Repair

Edwards Lifesciences Corp. announced the successful completion of the first three human implants of its Fortis mitral transcatheter ...

TAVR Heart valve repair Hybrid OR Edwards Lifesciences Sapien

At age 88, Lena M. Smith visited her doctor, Larry Hunt, M.D., at the University of Alabama at Birmingham to find out why her energy level had diminished. 

Boston Scientific Lotus Aortic Valve Repair Heart Hybrid OR Cath Lab

Boston Scientific’s Lotus transcatheter aortic valve repair (TAVR) system was implanted for the first...

Ademedus CardioCel Stem Cell Therapy

The U.S. Food and Drug Administration (FDA) cleared Admedus’s CardioCel, a tissue product to repair and treat a range of cardiovascular and vascular defects. The company is looking to complement...